Lisa M. Meckley, Ph.D.
Affiliations: | 2008 | University of Washington, Seattle, Seattle, WA |
Area:
Pharmacology, Pharmaceutical ChemistryGoogle:
"Lisa Meckley"Parents
Sign in to add mentor| David L. Veenstra | grad student | 2008 | University of Washington | |
| (Clinical utility, cost -effectiveness and provider perceptions of CYP2C9 and VKORC1 genotyping for chronic warfarin therapy.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Cox JB, Cangelosi MJ, Ortendahl JD, et al. (2015) Cost-Effectiveness of Bronchial Thermoplasty in Patients with Poorly Controlled, Severe, Persistent Asthma Journal of Allergy and Clinical Immunology. 135: AB49 |
| Montero AJ, Meckley LM, Anene AM, et al. (2014) Cost-effectiveness of metal stents in pancreatic cancer. Journal of Clinical Oncology. 32: 260-260 |
| Giovanni MA, Fickie MR, Lehmann LS, et al. (2010) Health-care referrals from direct-to-consumer genetic testing. Genetic Testing and Molecular Biomarkers. 14: 817-9 |
| Meckley LM, Gudgeon JM, Anderson JL, et al. (2010) A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics. 28: 61-74 |
| Meckley LM, Greenberg D, Cohen JT, et al. (2010) The adoption of cost-effectiveness acceptability curves in cost-utility analyses. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 30: 314-9 |
| Meckley LM, Wittkowsky AK, Rieder MJ, et al. (2008) An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients Thrombosis and Haemostasis. 100: 229-239 |
| Garrison LP, Carlson RJ, Carlson JJ, et al. (2008) A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metabolism Reviews. 40: 377-401 |
| Meckley L, Gudgeon J, Anderson J, et al. (2008) PHP72 GENETIC TESTING FOR WARFARIN INITIATION: A COST-EFFECTIVENESS ANALYSIS BASED ON CURRENT EVIDENCE Value in Health. 11: A51 |
| Gudgeon J, Williams M, Anderson J, et al. (2007) PCASE10 SHOULD GENETIC TESTING BE USED TO GUIDE WARFARIN THERAPY? Value in Health. 10: A205-A206 |
| Meckley L, Austin M, Garrison L, et al. (2007) PCV56 THE COST-EFFECTIVENESS LANDSCAPE OF GENETIC TESTING WITH WARFARIN THERAPY Value in Health. 10: A53 |